Post by icemandios on Jun 18, 2018 13:10:14 GMT
Eloxx Appoints Global Pharmaceutical Leader, Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary
“We are extremely pleased to have attracted someone with Neil’s extensive legal, business, and transactional experience to our leadership team,” said Robert E. Ward, Chairman and CEO of Eloxx. “I believe that Neil’s experiences advising public companies through the full development life-cycle and his knowledge of the global biopharmaceutical industry, as well as his expertise in corporate governance and compliance, will add significant value to the Company as it matures.”
“I am excited to be joining the Eloxx leadership team and look forward to contributing to the rapid growth and success of the Company,” said Mr. Belloff. “I am honored to have the opportunity to be a part of an innovative company with the potential to have a substantial impact on the lives of patients with rare diseases.”
Prior to joining Eloxx and Celgene Corporation, Mr. Belloff was EVP and U.S. Corporate and Securities Counsel at Deutsche Telecom, one of the largest telecommunications companies in the world. Mr. Belloff was affiliated with various New York-based law firms and as a Senior Attorney-Advisor in the Division of Corporation Finance at the U.S. Securities and Exchange Commission in Washington, D.C. Mr. Belloff holds a J.D. from Quinnipiac University School of Law, an M.A. from New York University, a B.A. from Queens College of the City University of New York, and completed post-graduate studies in the LLM Program in Securities Regulation at Georgetown University Law Center.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. ELX-02 is in the early stages of clinical development focusing on cystic fibr